Mechanisms of action and resistance for multiple myeloma novel drug treatments.

about

Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study.

P2860

Q50204319-AC6BC009-4A22-4710-9A34-67634F5373C5

P2860

Mechanisms of action and resistance for multiple myeloma novel drug treatments.

Item

http://www.wikidata.org/entity/Q38860769

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Mechanisms of action and resistance for multiple myeloma novel drug treatments.

@en

type

Item

label

Mechanisms of action and resistance for multiple myeloma novel drug treatments.

@en

prefLabel

Mechanisms of action and resistance for multiple myeloma novel drug treatments.

@en

P1476

Mechanisms of action and resistance for multiple myeloma novel drug treatments.

@en

P2093

Shinsuke Iida

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a primary target of thalidomide teratogenicity

Initial genome sequencing and analysis of multiple myeloma

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

P2888

s12185-016-2040-0

P304

271-272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12185-016-2040-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1013322731

http://www.w3.org/2001/XMLSchema#string

P698

27283410

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance

Mechanisms of action and resistance for multiple myeloma novel drug treatments.

about

P2860

P2860

Mechanisms of action and resistance for multiple myeloma novel drug treatments.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921